JNJ vs NVS vs SNY Stock Comparison

Johnson & Johnson, Novartis Ag and Sanofi Prices as of Nov 13, 2026 Peers: Industry group
JNJ Johnson & Johnson
$286.11 +12.7% 1M +46.5% 1Y
Market cap
$681.31B
P/E
42.3x
Revenue (TTM)
$99.34B
Div. yield
0.02%
Pharmaceuticals Healthcare
4 wins
NVS Novartis Ag
$160.55 +9.3% 1M +21.7% 1Y
Market cap
$310.90B
P/E
17.9x
Revenue (TTM)
—
Div. yield
–
Pharmaceuticals Healthcare
1 win
SNY Sanofi
$48.37 +21.6% 1M -7.6% 1Y
Market cap
$59.05B
P/E
6.2x
Revenue (TTM)
$55.00B
Div. yield
–
Pharmaceuticals Healthcare
4 wins

Head to Head

9 decided of 12

Johnson & Johnson leads on 4 of the 12 questions below (Johnson & Johnson 4, Sanofi 4, Novartis Ag 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionJNJNVSSNYLeader
Larger companyMarket capitalisation $681.31B $310.90B $59.05B JNJ
Cheaper on earningsLower P/E, profitable companies only 42.3x 17.9x 6.2x SNY
Cheaper on forward earningsLower price / next fiscal year consensus EPS 26.7x 17.1x 10.4x SNY
Faster revenue growthRevenue growth, trailing twelve months +7.8% — -19.6% JNJ
More profitableNet margin, trailing twelve months 16.2% — 17.2% SNY
Better return on capitalReturn on invested capital 17.6% — — –
Less leveragedLower net debt / EBITDA 0.8x — — –
Higher dividend yieldTrailing dividend yield 0.02% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +46.5% +21.7% -7.6% JNJ
Better 5-year returnAnnualised price return, 5 years +11.6%/yr +14.3%/yr -1.0%/yr NVS
Less volatileAnnualised volatility, 1 year 21.2% 27.8% 24.1% JNJ
Higher overall scoreMean of the five percentile scores vs peers 65/100 — 83/100 SNY

Percentile Scorecard

JNJNVSSNY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisJNJNVSSNY
Valuation 84 #104 of 660 96 #26 of 660 99 #11 of 660
Growth 34 #410 of 619 – 55 #280 of 619
Profitability 94 #39 of 595 – 95 #30 of 595
Financial Health 39 #416 of 683 – –
Shareholder Returns 73 #123 of 459 79 #97 of 459 85 #68 of 459
Overall 65 – 83
  • JNJ ranked among 695 companies in Pharmaceuticals and Biotechnology
  • NVS ranked among 695 companies in Pharmaceuticals and Biotechnology
  • SNY ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodJNJNVSSNYSPY
1 month +12.7%+9.3%+21.6% -2.0%
3 months +9.9%+6.4%+10.6% -2.8%
6 months +26.2%+8.4%+13.3% +2.0%
Year to date +38.3%+16.5%-0.2% +10.6%
1 year +46.5%+21.7%-7.6% +12.2%
3 years +93.8%+69.2%+5.8% +68.1%
3 years, per year +24.7%+19.2%+1.9% +18.9%
5 years +73.4%+94.6%-4.7% +61.4%
5 years, per year +11.6%+14.3%-1.0% +10.1%
10 years +141.5%+118.5%+17.9% +248.5%
10 years, per year +9.2%+8.1%+1.7% +13.3%

Risk

MeasureJNJNVSSNYSPY
Volatility, 1Y 21.2%27.8%24.1% 13.6%
Downside volatility, 1Y 20.1%30.0%24.8% 13.9%
Beta vs S&P 500, 1Y -0.090.360.28 1.00
Return / volatility, 1Y 2.190.78-0.31 0.90
Max drawdown, 5Y -23.6%-20.4%-35.2% -25.4%
From 52-week high 0.0%-4.8%-7.6% -3.2%
52-week high $286.11$168.62$52.34 $779.14
52-week low $195.25$124.36$39.12 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleJNJNVSSNY
P/E now vs peer median 42.8xmedian 17.0x 17.9xmedian 17.0x 6.2xmedian 17.0x
P/S now vs peer median 6.9xmedian 8.4x 5.1xmedian 8.4x 1.1xmedian 8.4x
EV/EBITDA now vs peer median 21.5xmedian 14.6x —median 14.6x 8.5xmedian 14.6x
P/FCF now vs peer median 33.5xmedian 19.0x 14.3xmedian 19.0x 4.1xmedian 19.0x
P/B now vs peer median 8.4xmedian 2.0x —median 2.0x —median 2.0x
PEG now vs peer median -1.42median 0.43 —median 0.43 24.27median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsJNJNVSSNY
Revenue $99.34B – $55.00B
Gross profit $67.11B – $63.47B
Operating income $25.19B – $11.14B
Net income $16.10B – $7.19B
Free cash flow $20.59B – $14.54B
R&D $16.08B – $17.81B
EPS (diluted) $6.57 – $7.72
Cash & equivalents $16.91B $400.00M $6.77B
Total debt $44.65B – –
Shares (diluted) 2.45B 1.96B 1.23B
Enterprise value $601.18B $284.14B $29.25B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricJNJNVSSNY
P/E 42.8x 17.9x 6.2x
P/FCF 33.5x 14.3x 4.1x
P/Operating cash flow 26.3x – 3.2x
P/S 6.9x 5.1x 1.1x
P/B 8.4x – –
P/Tangible book 19.7x – –
EV/EBITDA 21.5x – 8.5x
EV/EBIT 28.4x – 4.7x
EV/Revenue 7.2x – 0.9x
EV/FCF 34.8x – 3.6x
EV/Operating cash flow 27.4x – 2.8x
PEG (3Y EPS CAGR) -1.42 – 24.27

Growth

14 metrics
MetricJNJNVSSNY
Revenue growth (1Y) 7.8% – -19.6%
Revenue CAGR (3Y) -14.5% – 6.3%
Gross profit growth (1Y) 7.0% – 86.6%
Gross profit CAGR (3Y) -12.3% – 23.2%
Operating income growth (1Y) 7.4% – 24.9%
Operating income CAGR (3Y) -12.8% – -3.4%
Net income growth (1Y) -35.9% – -30.1%
Net income CAGR (3Y) -31.0% – -9.6%
EPS growth (1Y) -36.4% – -12.4%
EPS CAGR (3Y) -30.1% – 0.3%
Operating cash flow growth (1Y) 8.1% – 45.1%
Operating cash flow CAGR (3Y) 11.4% – 20.9%
Free cash flow growth (1Y) 5.1% – -10.0%
Free cash flow CAGR (3Y) 8.8% – 11.9%

Profitability

14 metrics
MetricJNJNVSSNY
Gross margin 67.6% – 115.4%
EBITDA margin 33.5% – 11.2%
Operating margin 25.4% – 20.3%
Pretax margin 17.9% – 22.9%
Net margin 16.2% – 17.2%
FCF margin 20.7% – 26.4%
Operating cash flow margin 26.3% – 33.5%
Return on equity 19.3% – –
Return on assets 8.1% – 4.9%
Return on invested capital 17.6% – –
Return on capital employed 17.5% – –
Asset turnover 0.5x – 0.4x
Cash conversion (OCF / net income) 1.6x – 2.6x
Stock comp / revenue 1.4% – –

Financial Health

11 metrics
MetricJNJNVSSNY
Debt / assets 22.6% – –
Debt / equity 0.5x – –
Net debt / EBITDA 0.8x – –
Debt / FCF 2.2x – –
Liabilities / assets 58.7% – –
Equity / assets 41.3% – –
Interest coverage 25.6x – 11.9x
Current ratio 1.0x – –
Quick ratio 0.7x – –
Cash ratio 0.3x – –
Altman Z-score 5.69 – –

Shareholder Returns

7 metrics
MetricJNJNVSSNY
Dividend yield 1.8% 3.0% 5.0%
Net buyback yield 0.6% – -0.2%
Shareholder yield 2.4% 3.0% 4.8%
Payout ratio (earnings) 79.0% – –
Payout ratio (FCF) 61.8% – –
Dividend growth (1Y) 3.9% – –
Dividend CAGR (3Y) 2.8% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusJNJNVSSNY
Forward P/E 26.7xFY2026 17.1xFY2026 10.4xFY2026
EPS, next fiscal year $10.72FY2026 $9.38FY2026 $4.67FY2026
EPS growth, next FY -0.6%FY2026 +4.5%FY2026 0.0%FY2026
EPS growth, the year after +5.8% +0.9% +5.8%
Revenue, next fiscal year $106.55BFY2026 $53.97BFY2026 $54.79BFY2026
Revenue growth, next FY +13.1%FY2026 -1.0%FY2026 -0.5%FY2026
Revenue growth, the year after +6.8% +19.3% +14.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersJNJNVSSNY
Held by institutions 74.7% 7.0% 15.5%
Institutions holding 4,699 1,610 719
Change in shares held, QoQ +1.8% -6.0% -9.8%
Institutions buying 2,297 662 304
Institutions selling 1,899 562 294
Buyers to sellers 1.21 1.18 1.03

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

JNJNVSSNY
JNJ 1.00 0.51 0.42
NVS 0.51 1.00 0.46
SNY 0.42 0.46 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, JNJ, NVS and SNY?

Johnson & Johnson (JNJ) is the largest by market capitalisation: Johnson & Johnson (JNJ) $681.31B, Novartis Ag (NVS) $310.90B, Sanofi (SNY) $59.05B.

Which stock is cheaper, JNJ, NVS and SNY?

Sanofi (SNY) trades on the lowest price-to-earnings ratio (Johnson & Johnson (JNJ) 42.3x, Novartis Ag (NVS) 17.9x, Sanofi (SNY) 6.2x). On next year's consensus earnings, Sanofi (SNY) is cheapest (Johnson & Johnson (JNJ) 26.7x, Novartis Ag (NVS) 17.1x, Sanofi (SNY) 10.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Johnson & Johnson (JNJ) grew revenue fastest over the trailing twelve months: Johnson & Johnson (JNJ) +7.8%, Sanofi (SNY) -19.6%.

Which company is more profitable?

Sanofi (SNY) has the highest net margin (Johnson & Johnson (JNJ) 16.2%, Sanofi (SNY) 17.2%).

Which stock has performed better?

Over the past year Johnson & Johnson (JNJ) returned the most: Johnson & Johnson (JNJ) +46.5%, Novartis Ag (NVS) +21.7%, Sanofi (SNY) -7.6%. Over five years, Novartis Ag (NVS) compounded fastest (Johnson & Johnson (JNJ) +11.6%/yr, Novartis Ag (NVS) +14.3%/yr, Sanofi (SNY) -1.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Johnson & Johnson (JNJ) 0.02%, Novartis Ag (NVS) 0.00%, Sanofi (SNY) 0.00%. Novartis Ag (NVS) and Sanofi (SNY) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Johnson & Johnson (JNJ) has been the steadiest (Johnson & Johnson (JNJ) 21.2%, Novartis Ag (NVS) 27.8%, Sanofi (SNY) 24.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, JNJ, NVS and SNY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Johnson & Johnson (JNJ) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.